醛固酮合酶抑制剂vicadrostat改善CKD心肾结局的潜在作用:EASi-KIDNEY试验依据
尽管现有RASi、SGLT2i和他汀类治疗,CKD患者仍面临肾功能进展、心衰和心血管死亡风险。靶向醛固酮通路可能进一步降低心肾风险,II期数据显示ASi vicadrostat 10mg使白蛋白尿CKD患者UACR降低约40%。
要点
- RASi和SGLT2i针对CKD进展的最终共同通路,但残余风险仍高。
- ASi vicadrostat 10mg在II期研究中降低白蛋白尿CKD患者UACR约40%。
- EASi-KIDNEY试验将评估vicadrostat联合恩格列净在CKD患者中的心肾获益。
核心结论
- 抑制醛固酮通路可能为更广泛的CKD患者(包括非糖尿病或低白蛋白尿者)提供心肾保护。
- ASi vicadrostat联合SGLT2i有望减轻高钾血症风险,扩大治疗人群。
- EASi-KIDNEY试验将验证vicadrostat联合恩格列净在CKD患者中的安全性和心肾疗效。
研究设计与样本
- II期数据来自586例白蛋白尿CKD患者,评估vicadrostat(BI 690517)10mg的疗效。
主要发现
- II期数据显示,vicadrostat 10mg相比安慰剂使白蛋白尿CKD患者UACR降低约40%,无论是否联用恩格列净。
- 非甾体类MRA在已接受RASi治疗的糖尿病肾病伴白蛋白尿患者中可降低心肾风险。
- MRA和ASi均增加高钾血症风险,与SGLT2i联用可能减轻该风险。
关键数值与推荐
- II期研究:vicadrostat 10mg使UACR降低约40%(对比安慰剂,n=586)。
临床怎么用
- 对于已接受RASi和SGLT2i但仍有残余心肾风险的CKD患者,可考虑醛固酮通路抑制。
- ASi联合SGLT2i可能改善耐受性,使血钾较高或非糖尿病CKD患者也能接受治疗。
- 临床使用ASi或MRA时需监测血钾,联用SGLT2i可能有助于管理高钾血症风险。
局限性
- II期数据仅限于白蛋白尿CKD患者,非糖尿病或低白蛋白尿人群的疗效尚未验证。
- EASi-KIDNEY试验结果尚未公布,vicadrostat联合恩格列净的安全性和心肾获益有待确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with chronic kidney disease (CKD) are at risk of progressive loss of kidney function, heart failure, and cardiovascular death despite current proven therapies, including renin-angiotensin system inhibitors (RASi), sodium glucose co-transporter-2 inhibitors (SGLT2i), and statin-based regimens. RASi and SGLT2i reduce risk of CKD progression irrespective of primary cause of kidney disease, suggesting they target final common pathways. Targeting aldosterone overactivity with a nonsteroidal mineralocorticoid receptor antagonist (MRA) also reduces cardiorenal risk in patients with albuminuric diabetic kidney disease already treated with RASi. Together, these observations provide the rationale for trials to assess effects of inhibiting the aldosterone pathway in a broader range of patients with CKD, including those with non-diabetic causes of CKD or low albuminuria. Aldosterone synthase inhibitors (ASi) have emerged as an alternative to MRAs for aldosterone pathway inhibition. Phase II data from 586 patients with albuminuric CKD have shown that 10 mg of an ASi, vicadrostat (BI 690517), reduced urine albumin-to-creatinine ratio by ∼40% compared with placebo, with or without concurrent empagliflozin treatment. MRA and ASi increase risk of hyperkalaemia. Combining their use with an SGLT2i may mitigate some of this risk, improving tolerability, and allowing a wider range of patients to be treated (including those with higher levels of blood potassium than in previous trials). The EASi-KIDNEY (NCT06531824) double-blind placebo-controlled trial will test this approach by assessing the safety and cardiorenal efficacy of vicadrostat in combination with empagliflozin in ∼11 000 patients with CKD. It will be sufficiently large to assess effects in patients with and without diabetes separately.
引用
- Judge PK, Tuttle KR, Staplin N, et al. The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial. Nephrol Dial Transplant. 2025. PMID: 39533115. doi:10.1093/ndt/gfae263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。